Prostanoids in the therapy of glaucoma

Cardiovasc Drug Rev. 2006 Spring;24(1):1-10. doi: 10.1111/j.1527-3466.2006.00001.x.


Elevated intraocular pressure (IOP) is one of the most important risk factors for the development of glaucoma, which is a progressive optic neuropathy. Lowering IOP is currently the only therapeutic approach to the therapy of glaucoma. Since the use of pilocarpine eye drops for glaucoma treatment was reported in the late 1870s, academic researchers and pharmaceutical companies attempted to discover new drugs with more potent, prolonged, and safer IOP-reducing effects. These persistent efforts finally paid off, and prostanoids with FP-receptor agonist activity were found to be very potent IOP-lowering agents. To date, three prostanoids (latanoprost, travoprost and bimatoprost) have been launched in many countries, and now a new FP-receptor agonist, tafluprost, is entering clinical development. All of these prostanoids are superior to the beta-adrenoceptor antagonists in their IOP-lowering efficacy, and no severe side effects have been reported in their long-term clinical use. In addition, tafluprost may be expected to improve ocular blood flow. Hence, prostanoids currently occupy center stage among glaucoma medications. It cannot be denied that in terms of efficacy, safety, patient compliance, and medical economy prostanoids are currently the first-line medicines among ocular antihypertensive drugs.

Publication types

  • Review

MeSH terms

  • Glaucoma / drug therapy*
  • Humans
  • Intraocular Pressure / drug effects*
  • Prostaglandins* / pharmacology
  • Prostaglandins* / therapeutic use
  • Randomized Controlled Trials as Topic
  • Receptors, Prostaglandin / agonists


  • Prostaglandins
  • Receptors, Prostaglandin
  • prostaglandin F2alpha receptor